Zacks: Brokerages Anticipate bluebird bio Inc (BLUE) Will Post Earnings of -$2.83 Per Share

Share on StockTwits

Wall Street brokerages predict that bluebird bio Inc (NASDAQ:BLUE) will post earnings of ($2.83) per share for the current fiscal quarter, according to Zacks. Eight analysts have provided estimates for bluebird bio’s earnings, with estimates ranging from ($3.20) to ($2.55). bluebird bio reported earnings of ($2.52) per share in the same quarter last year, which indicates a negative year-over-year growth rate of 12.3%. The firm is expected to issue its next earnings results on Wednesday, February 20th.

According to Zacks, analysts expect that bluebird bio will report full year earnings of ($10.76) per share for the current fiscal year, with EPS estimates ranging from ($11.17) to ($10.25). For the next fiscal year, analysts expect that the firm will post earnings of ($11.52) per share, with EPS estimates ranging from ($12.95) to ($9.13). Zacks’ EPS averages are a mean average based on a survey of research firms that cover bluebird bio.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings results on Thursday, November 1st. The biotechnology company reported ($2.73) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.90) by $0.17. The firm had revenue of $11.50 million during the quarter, compared to the consensus estimate of $6.90 million. bluebird bio had a negative return on equity of 31.50% and a negative net margin of 1,326.02%. The firm’s quarterly revenue was up 49.2% compared to the same quarter last year. During the same period in the prior year, the company posted ($1.73) earnings per share.

BLUE has been the subject of a number of research analyst reports. Cantor Fitzgerald set a $122.00 price target on bluebird bio and gave the company a “sell” rating in a report on Wednesday, September 5th. ValuEngine raised bluebird bio from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 2nd. Piper Jaffray Companies downgraded bluebird bio from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $240.00 to $120.00 in a report on Thursday. Oppenheimer reaffirmed a “hold” rating on shares of bluebird bio in a report on Tuesday, November 27th. Finally, William Blair reaffirmed a “buy” rating on shares of bluebird bio in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and seventeen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $194.80.

In other bluebird bio news, Director James Mandell sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, September 10th. The stock was sold at an average price of $150.77, for a total value of $150,770.00. Following the completion of the sale, the director now owns 1,568 shares in the company, valued at $236,407.36. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider David Davidson sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, October 2nd. The shares were sold at an average price of $139.32, for a total value of $696,600.00. Following the completion of the sale, the insider now owns 29,905 shares of the company’s stock, valued at approximately $4,166,364.60. The disclosure for this sale can be found here. In the last quarter, insiders sold 21,490 shares of company stock valued at $2,901,186. 3.00% of the stock is owned by company insiders.

Several institutional investors have recently added to or reduced their stakes in BLUE. Stratos Wealth Partners LTD. purchased a new stake in shares of bluebird bio during the third quarter worth approximately $106,000. Belpointe Asset Management LLC purchased a new stake in shares of bluebird bio during the third quarter worth approximately $110,000. NuWave Investment Management LLC raised its stake in shares of bluebird bio by 10,811.1% during the third quarter. NuWave Investment Management LLC now owns 982 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 973 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its stake in shares of bluebird bio by 635.0% during the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,154 shares of the biotechnology company’s stock worth $167,000 after purchasing an additional 997 shares during the last quarter. Finally, Tower Research Capital LLC TRC purchased a new stake in shares of bluebird bio during the second quarter worth approximately $201,000.

BLUE traded down $6.62 on Friday, reaching $102.23. The company’s stock had a trading volume of 1,024,569 shares, compared to its average volume of 690,709. The company has a market capitalization of $5.95 billion, a price-to-earnings ratio of -13.26 and a beta of 2.37. bluebird bio has a fifty-two week low of $100.99 and a fifty-two week high of $236.17.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Featured Article: Fundamental Analysis – How It Helps Investors

Get a free copy of the Zacks research report on bluebird bio (BLUE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply